Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors

References

• Klenerman P, Gupta PK. Hepatitis C virus: current concepts and future challenges. QJM 2012;105:29–32
   PubMed Web of Science ®Google Scholar
• WHO. Hepatitis C, 2012. Fact sheet N°164
   Google Scholar
• Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962–73
   PubMed Web of Science ®Google Scholar
• Tse MT, Kirkpatrick P. 2012 in reflection. Nat Rev Drug Discov 2012;12:8–10
   Web of Science ®Google Scholar
• Morikawa K, Lange CM, Gouttenoire J, et al. Nonstructural protein 3-4 A: the Swiss army knife of hepatitis C virus. J Viral Hepat 2011;18:305–15
   PubMed Web of Science ®Google Scholar
• Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007;5:453–63
   PubMed Web of Science ®Google Scholar
• Raney KD, Sharma SD, Moustafa IM, Cameron CE. Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J Biol Chem 2010;285:22725–31
   PubMed Web of Science ®Google Scholar
• Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996;87:343–55
   PubMed Web of Science ®Google Scholar
• Dahl G, Sandström A, Åkerblom E, Danielson UH. Effects on protease inhibition by modifying of helicase residues in hepatitis C virus nonstructural protein 3. FEBS J 2007;274:5979–86
   PubMed Web of Science ®Google Scholar
• Beran RK, Lindenbach BD, Pyle AM. The NS4A protein of hepatitis C virus promotes RNA-coupled ATP hydrolysis by the NS3 helicase. J Virol 2009;83:3268–75
   PubMed Web of Science ®Google Scholar
• Xue W, Wang M, Jin X, et al. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4 A: insights from molecular dynamics simulation, binding free energy calculation and network analysis. Mol Biosyst 2012;8:2753–65
   PubMed Web of Science ®Google Scholar
• Saalau-Bethell SM, Woodhead AJ, Chessari G, et al. Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat Chem Biol 2012;8:920–5
   PubMed Web of Science ®Google Scholar
• Ingallinella P, Altamura S, Bianchi E, et al. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry 1998;37:8906–14
   PubMed Web of Science ®Google Scholar
• Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186–9
   PubMed Web of Science ®Google Scholar
• Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004;127:1347–55
   PubMed Web of Science ®Google Scholar
• Seiwert SD, Andrews SW, Jiang Y, et al. Preclinical characteristics of the hepatitis C virus NS3/4 A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 2008;52:4432–41
   PubMed Web of Science ®Google Scholar
• Rajagopalan R, Misialek S, Stevens SK, et al. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. Biochemistry 2009;48:2559–68
   PubMed Web of Science ®Google Scholar
• Tong J, Wang Y-w, Lu Y-a. New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy. J Zhejiang Univ Sci B 2012;13:56–82
   PubMed Web of Science ®Google Scholar
• Lin C, Lin K, Luong Y-P, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2004;279:17508–14
   PubMed Web of Science ®Google Scholar
• Mullard A. 2011 FDA drug approvals. Nat Rev Drug Discov 2012;11:91–4
   PubMed Web of Science ®Google Scholar
• Poliakov A, Hubatsch I, Shuman CF, et al. Expression and purification of recombinant full-length NS3 protease-helicase from a new variant of Hepatitis C virus. Protein Expr Purif 2002;25:363–71
   PubMed Web of Science ®Google Scholar
• Dahl G, Sandström A, Åkerblom E, Danielson UH. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3. Antivir Ther 2007;12:733–40
   PubMed Web of Science ®Google Scholar
• Gallinari P, Brennan D, Nardi C, et al. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J Virol 1998;72:6758–69
   PubMed Web of Science ®Google Scholar
• Gallinari P, Paolini C, Brennan D, et al. Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A. Biochemistry 1999;38:5620–32
   PubMed Web of Science ®Google Scholar
• Liu Y, Kati W, Chen CM, et al. Use of a fluorescence plate reader for measuring kinetic parameters with inner filter effect correction. Anal Biochem 1999;267:331–5
   PubMed Web of Science ®Google Scholar
• Gulnik SV, Suvorov LI, Liu B, et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995;34:9282–7
   PubMed Web of Science ®Google Scholar
• Dahl G, Arenas OG, Danielson UH. Hepatitis C virus NS3 protease is activated by low concentrations of protease inhibitors. Biochemistry 2009;48:11592–602
   PubMed Web of Science ®Google Scholar
• Zhu H, Briggs JM. Mechanistic role of NS4A and substrate in the activation of HCV NS3 protease. Proteins 2011;79:2428–43
   PubMed Web of Science ®Google Scholar
• Misialek S, Rajagopalan R, Stevens SK, et al. Optimization of the multiple enzymatic activities of the hepatitis C virus NS3 protein. Analytical Biochem 2009;394:138–40
   PubMed Web of Science ®Google Scholar
• Urbani A, Biasiol G, Brunetti M, et al. Multiple determinants influence complex formation of the hepatitis C virus NS3 protease domain with its NS4A cofactor peptide. Biochemistry 1999;38:5206–15
   PubMed Web of Science ®Google Scholar
• Dominguez JL, Christopeit T, Villaverde MC, et al. Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE-1. Biochemistry 2010;49:7255–63
   PubMed Web of Science ®Google Scholar
• Geitmann M, Dahl G, Danielson UH. Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors. J Mol Recogn 2011;24:60–70
   PubMed Web of Science ®Google Scholar
• Romano KP, Ali A, Aydin C, et al. The molecular basis of drug resistance against hepatitis C virus NS3/4 A protease inhibitors. PLoS Pathol 2012;8:e1002832
   PubMed Web of Science ®Google Scholar